<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2221">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589949</url>
  </required_header>
  <id_info>
    <org_study_id>NL74972.078.20</org_study_id>
    <nct_id>NCT04589949</nct_id>
  </id_info>
  <brief_title>Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)</brief_title>
  <acronym>CoV-Early</acronym>
  <official_title>Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanquin Plasma Products BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An effective, widely available, and safe treatment that can decrease the duration, severity&#xD;
      and fatality of COVID-19 is urgently needed. Also, in the most affected regions the pressure&#xD;
      on health care systems including ventilator support capacity can be a limiting factor for&#xD;
      survival. Initial studies including from our group indicate that administering convalescent&#xD;
      plasma containing high titers of neutralizing antibodies to COVID-19 patients who are already&#xD;
      relatively late during the disease course after hospital admission is not effective, which&#xD;
      can be explained by high titers of autologous antibodies present in patients. Thus, the&#xD;
      antiviral capacity of convalescent plasma is hypothesized to be best positioned early in the&#xD;
      disease course and in patients at increased risk for a severe disease course. If effective,&#xD;
      any treatment that decreases the need for hospital admission is very valuable but so far, no&#xD;
      COVID-19 treatment has been shown to prevent clinical deterioration when given before&#xD;
      patients are admitted to the hospital.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To evaluate the efficacy, feasibility and safety following the administration of convalescent&#xD;
      plasma (ConvP) as a therapy for outpatients diagnosed with COVID-19 at increased risk for an&#xD;
      unfavourable clinical outcome and within 7 days after symptom onset.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      This trial is a nationwide multicenter, double blind, randomized controlled trial in the&#xD;
      Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus&#xD;
      regular fresh frozen plasma (FFP).&#xD;
&#xD;
      Patient population:&#xD;
&#xD;
      Patients with polymerase chain reaction (PCR) confirmed COVID disease with less than 8 days&#xD;
      of symptoms, age 70 or older or 50-69 years with at least 1 additional risk factor for severe&#xD;
      COVID-19 are eligible.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      300mL of convP with a minimum level of neutralizing antibodies.&#xD;
&#xD;
      A total of 690 patients will be included. Expected duration of accrual: 18-24 months Duration&#xD;
      of follow up :Day 28 for the primary endpoint&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary (exploratory) objectives&#xD;
&#xD;
        -  To evaluate the impact of 300mL convP on mortality&#xD;
&#xD;
        -  To evaluate the impact of 300mL convP on hospital admission&#xD;
&#xD;
        -  To evaluate the impact of 300mL convP on admission to ICU&#xD;
&#xD;
        -  To evaluate the impact of 300mL convP on duration of symptoms&#xD;
&#xD;
        -  To evaluate the impact of 300mL convP in relation to the age and clinical frailty of the&#xD;
           patient&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Highest disease status</measure>
    <time_frame>28 days following transfusion of convP or FFP</time_frame>
    <description>Highest disease status on the 5-point ordinal disease severity scale in the convP group will be compared with the FFP group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of deaths</measure>
    <time_frame>28 days following transfusion of convP or FFP</time_frame>
    <description>Percentage of deaths in the convP group compared to the FFP group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of hospital admissions</measure>
    <time_frame>28 days following transfusion of convP or FFP</time_frame>
    <description>Percentage of hospital admissions in the convP group compared to the FFP group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ICU admissions</measure>
    <time_frame>28 days following transfusion of convP or FFP</time_frame>
    <description>Percentage of ICU admissions in the convP group compared to the FFP group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease duration in days of symptoms</measure>
    <time_frame>28 days following transfusion of convP or FFP</time_frame>
    <description>Disease duration in days of symptoms in the convP group compared to the FFP group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age and clinical frailty score</measure>
    <time_frame>28 days following transfusion of convP or FFP</time_frame>
    <description>Age and clinical frailty score stratified analysis of percentage of primary endpoint following transfusion of convP versus FFP.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Highest disease status stratified by presence of neutralizing antibodies and by symptom duration at baseline</measure>
    <time_frame>28 days following transfusion of convP or FFP</time_frame>
    <description>Analysis of primary endpoint following transfusion of convP versus FFP stratified by the presence of neutralizing antibodies at baseline and by symptom duration at baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in proportion of detectable SARS-Cov-2 RT-PCR results</measure>
    <time_frame>Day 3, 7, 14 and 28 following transfusion of convP or FFP</time_frame>
    <description>Change in proportion of detectable SARS-CoV-2 RT-PCR results at day 3, 7, 14 and 28 following transfusion according to the presence of neutralizing antibodies at baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">690</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ConvP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mL convalescent plasma with a minimum of neutralizing antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mL Fresh Frozen plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ConvP</intervention_name>
    <description>Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.&#xD;
Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products</description>
    <arm_group_label>ConvP</arm_group_label>
    <other_name>convalescent plasma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FFP</intervention_name>
    <description>Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products</description>
    <arm_group_label>FFP</arm_group_label>
    <other_name>Fresh Frozen Plasma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  RT-PCR-confirmed COVID-19.&#xD;
&#xD;
          -  Symptomatic (e.g but not limited to fatigue, fever, cough, dyspnoea, loss of taste or&#xD;
             smell, diarrhea, falls or confusion)&#xD;
&#xD;
          -  70 years or older OR 50-69 years and 1 or more of the risk factors described in the&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt;28 days in the opinion of the treating physician&#xD;
&#xD;
          -  Patient or legal representative is unable to provide written informed consent&#xD;
&#xD;
          -  Symptomatic for 8 days or more&#xD;
&#xD;
          -  Being admitted to the hospital at the informed consent procedure&#xD;
&#xD;
          -  Known previous history of transfusion-related acute lung injury&#xD;
&#xD;
          -  Known Immunoglobulin A (IgA) deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Rijnders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bart Rijnders, MD, PhD</last_name>
    <phone>+31107033510</phone>
    <email>b.rijnders@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Rijnders, MD, PhD</last_name>
      <phone>+31104639222</phone>
      <phone_ext>35339</phone_ext>
      <email>b.rijnders@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Casper Rokx, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arvind Gharbharan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlijn Jordans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Jong, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert-Jan Hassing, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R.W. van Etten, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faiz Karim, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D. Postma, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Soetekouw, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L. Kampschreur, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JJ Zwaginga, MD/PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elana van Leeuwen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bernhoven Hospital</name>
      <address>
        <city>Uden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I Ludwig, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Bart Rijnders</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

